Research Paper Volume 12, Issue 15 pp 15656—15669

CTLA-4 immunotherapy exposes differences in immune response along with different tumor progression in colorectal cancer

class="figure-viewer-img"

Figure 1.

Different tumor sizes depending on the start treatment (100 to 800 mm3) of the subcutaneously inoculated CT26 show the different anti-tumor effects. The cell numbers of inoculation is 3 × 105 into 100 ul for each mouse. Tumor volume trace after administering anti-CTLA-4 Ab to female BALB/c mice inoculated with the CT26 syngeneic model. (A) Volume of tumors from mice inoculated with CT26 subcutaneously. Mean tumor volumes (mm3) ± SE (n = 5 mice per group) are shown. Data are statistically significant for anti-CTLA-4 antibody 10 mg/kg intraperitoneal injection, weekly; ***, P < 0.001, on day 17. (B) Photos of the tumors isolated from mice inoculated with CT26 cells in the study.